Management of Familial Hypercholesterolemia

Diagnosis

The American Heart Association suggests that an LDL cholesterol level of 243 mg/dL is well above the 190 mg/dL threshold for heterozygous familial hypercholesterolemia (HeFH) 1
A family history of premature cardiovascular disease, such as a father with myocardial infarction at age 45, is a significant risk factor for HeFH 1
Elevated lipoprotein(a) at 310.4 mg/dL is an independent risk factor for cardiovascular disease 1
Total cholesterol of 304 mg/dL is a significant risk factor for cardiovascular disease 1

The American College of Cardiology recommends initiating high-potency statin therapy in patients with HeFH, with a goal of reducing LDL-C by approximately 50% from baseline 3
A fat-modified, heart-healthy diet with saturated fat <7% of total calories, regular physical exercise, avoidance of tobacco products, and weight management if needed are essential lifestyle modifications for patients with HeFH 3
The primary target for treatment is to reduce LDL-C by approximately 50% from baseline, with a secondary target of achieving LDL-C <100 mg/dL given a family history of premature ASCVD 3

Baseline liver function tests, creatine kinase, glucose, and creatinine should be obtained before starting statin therapy, and liver enzymes should be monitored periodically while on statin therapy 3
Lipid profile should be repeated after 4-6 weeks of therapy to assess response, and treatment goals should be reassessed regularly 3
If treatment goals are not achieved with maximally tolerated statin plus ezetimibe, consider adding PCSK9 inhibitor therapy or plant sterols/stanols as adjunctive therapy 3

Family screening is essential to identify other affected individuals, and reverse-cascade screening of family members should be performed 2
Elevated lipoprotein(a) is an independent risk factor that may warrant more aggressive LDL-C lowering 1
Early initiation of therapy is critical, as evidence shows that early treatment of FH can significantly reduce lifetime cardiovascular risk 2

Undertreatment, relying solely on lifestyle modifications, would be insufficient for high-risk patients with HeFH 1
Delayed therapy would allow continued atherosclerotic progression, and inadequate monitoring would fail to assess adherence and response to therapy 3
Neglecting family screening would miss the opportunity to identify and treat other affected family members 2